Notice of Results

RNS Number : 1028L
Advanced Medical Solutions Grp PLC
27 July 2011

For Release: 27 July 2011


Advanced Medical Solutions Group plc



Notice of Interim Results


Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, will announce its interim results for the six months ended 30 June 2011 on Wednesday 7 September 2011.


A briefing for analysts will be held at 9.30am on the day of the results at the offices of Tavistock Communications, 131 Finsbury Pavement, London EC2A 1NT.


ends –


For further enquiries:


Advanced Medical Solutions Group plc                                                             

Chris Meredith, Chief Executive Officer

Mary Tavener, Finance Director


+44 (0) 1606 545508

Tavistock Communications                                                                                

John West / Chris Munden / Andrew Dunn


+44 (0) 20 7920 3150

Investec Bank plc                                                                                               

Gary Clarence / Patrick Robb / Daniel Adams


+44 (0) 20 7597 5970



About Advanced Medical Solutions Group plc – see


AMS’ advanced woundcare products are based on an extensive range of technologies including alginates, silver alginates and hydrophilic polyurethane foams. These and other products pioneer the concept of moist wound healing, allowing wounds to heal faster and with less pain and scarring. They protect the wound, deal with tissue fluids and provide an optimal environment for healing to occur. Silver is widely recognised as a safe and effective broad-spectrum anti-microbial agent for infection control.


AMS’ wound closure and sealants products are based on cyanoacrylate adhesive (“superglue”) technology developed for medical applications. Tissue adhesives offer significant benefits over conventional ways of closing wounds following trauma or surgical incision. They are simple to use, non-invasive, help to reduce the risk of infection, minimise trauma to the patient and provide good clinical and cosmetic outcomes. The technology is also ideally suited to protecting skin from breakdown or for use as a skin sealant to help prevent infection of surgical sites.



This information is provided by RNS
The company news service from the London Stock Exchange